BIOTECHNOLOGY PATENT THERAPY ANEMIA CHRONIC KIDNEY DISEASE

Head of POM Penny K. Lukito (left), President Commissioner of PT Kalbe Farma Tbk Irawati Setiadi (center) and President Director of PT Kalbe Farma Tbk Vidjongtius combined a press conference on Global Clinic Test Phase 3 Efepoetin Alfa for Chronic Kidney Disease Anemia Therapy, in Jakarta, Friday (24/1/2020). PT Kalbe Farma Tbk (Kalbe) through Kalbe-Genexine Bics’s subsidiary develops alpha-EPO-HYFC patent biotechnology drugs that are used for chronic kidney patient anemia therapy, which is currently the development has entered the 3 phase clinic test to test whether the drug has been effective and safe to use. ANTARA PHOTO/Audy Alwi/foc.

The caption is automatically translated by application. Click here for the Bahasa Indonesia version.